--- title: "Short Interest in Nukkleus Inc. (NASDAQ:NUKK) Grows By 25.2%" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/273005260.md" description: "Nukkleus Inc. (NASDAQ:NUKK) experienced a 25.2% increase in short interest in December, totaling 2,268,303 shares. Currently, 14.8% of its stock is short sold, with a days-to-cover ratio of 2.7 days. The stock price fell by 4.4% to $3.49, with a market cap of $58.11 million. Recent insider activity includes a major shareholder acquiring 255,000 shares and another insider selling 75,000 shares. Institutional investors hold 12.47% of the company. Analysts have mixed ratings, with one upgrade to a \"hold\" and others maintaining a \"sell\" rating." datetime: "2026-01-19T22:59:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273005260.md) - [en](https://longbridge.com/en/news/273005260.md) - [zh-HK](https://longbridge.com/zh-HK/news/273005260.md) --- > 支持的语言: [English](https://longbridge.com/en/news/273005260.md) | [繁體中文](https://longbridge.com/zh-HK/news/273005260.md) # Short Interest in Nukkleus Inc. (NASDAQ:NUKK) Grows By 25.2% Nukkleus Inc. (NASDAQ:NUKK - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 2,268,303 shares, an increase of 25.2% from the December 15th total of 1,811,274 shares. Based on an average daily trading volume, of 855,324 shares, the short-interest ratio is currently 2.7 days. Approximately 14.8% of the shares of the stock are short sold. Approximately 14.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 855,324 shares, the short-interest ratio is currently 2.7 days. ## Insider Activity In other news, major shareholder Sc Capital Ii Sponsor Llc acquired 255,000 shares of Nukkleus stock in a transaction that occurred on Friday, November 28th. The stock was bought at an average price of $10.00 per share, with a total value of $2,550,000.00. Following the completion of the purchase, the insider owned 255,000 shares in the company, valued at approximately $2,550,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Anastasiia Kotaieva sold 75,000 shares of the company's stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $4.09, for a total transaction of $306,750.00. Following the sale, the insider directly owned 75,000 shares in the company, valued at $306,750. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 394,952 shares of company stock worth $1,745,457. Company insiders own 7.90% of the company's stock. ## Hedge Funds Weigh In On Nukkleus Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in Nukkleus in the 2nd quarter worth $56,000. UBS Group AG grew its stake in shares of Nukkleus by 23.3% during the third quarter. UBS Group AG now owns 80,512 shares of the company's stock valued at $564,000 after buying an additional 15,223 shares during the last quarter. Finally, Ausdal Financial Partners Inc. bought a new position in shares of Nukkleus during the third quarter valued at about $105,000. Institutional investors own 12.47% of the company's stock. ## Nukkleus Stock Down 4.4% Shares of NASDAQ NUKK traded down $0.16 during trading hours on Monday, reaching $3.49. 3,304,601 shares of the stock traded hands, compared to its average volume of 1,239,930. The company has a market capitalization of $58.11 million, a P/E ratio of 0.21 and a beta of -6.67. The company's 50-day simple moving average is $4.84 and its two-hundred day simple moving average is $6.13. Nukkleus has a 52-week low of $3.31 and a 52-week high of $39.85. ## Wall Street Analysts Forecast Growth A number of research firms have recently commented on NUKK. Wall Street Zen upgraded shares of Nukkleus from a "sell" rating to a "hold" rating in a research report on Sunday, November 23rd. Weiss Ratings restated a "sell (d+)" rating on shares of Nukkleus in a research note on Wednesday, December 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of "Sell". **Check Out Our Latest Analysis on NUKK** ## Nukkleus Company Profile (Get Free Report) Nukkleus Inc, a financial technology company, provides blockchain-enabled technology solutions worldwide. It focuses on providing software and technology solutions for retail foreign exchange trading industry. The company provides transactions platform for dealing and risk management services. It also offers cross-border payment and transactions solutions and blockchain-enabled financial services solutions to institutional investors. In addition, the company provides software, technology, customer sales and marketing, and risk management technology hardware and software solutions. ## Recommended Stories - Five stocks we like better than Nukkleus - Elon Taking SpaceX Public! $100 Pre-IPO Opportunity! - How a Family Trust May Be Able To Help Preserve Your Wealth - Do not delete, read immediately - A U.S. “birthright” claim worth trillions - activated quietly - Executive Order 14330: Trump’s Biggest Yet _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Nukkleus Right Now? Before you consider Nukkleus, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nukkleus wasn't on the list. While Nukkleus currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### 相关股票 - [Nukkleus (NUKK.US)](https://longbridge.com/zh-CN/quote/NUKK.US.md) - [T3 Defense (DFNS.US)](https://longbridge.com/zh-CN/quote/DFNS.US.md) ## 相关资讯与研究 - [Varia US Properties Sets 2026 AGM to Confirm Governance and Strategy](https://longbridge.com/zh-CN/news/281470115.md) - [Nucor Corporation : US steel giant](https://longbridge.com/zh-CN/news/280968412.md) - [Zydus Lifesciences receives demand order for FY 2019-20 to FY 2023-24](https://longbridge.com/zh-CN/news/281307974.md) - [Brand House Collective Announced Transfer or Voluntary Withdrawal of Listing](https://longbridge.com/zh-CN/news/281572265.md) - [US farmers to plant less corn as Iran war spikes fertilizer prices](https://longbridge.com/zh-CN/news/281222140.md)